Citable company snapshot
GILEAD SCIENCES, INC.'s latest SEC-sourced 2026-03-31 period shows $6.96B in revenue and $2.02B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $6.96B | $7.92B | -12.2% |
| xbrl:GrossProfit | Dec 31, 2020 | $5.93B | $5.35B | +10.8% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $2.59B | $1.98B | +30.3% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $2.02B | $2.18B | -7.4% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $2.54B | $3.33B | -23.5% |
| Free Cash Flow (computed) | Mar 31, 2026 | $2.43B | $3.12B | -22.3% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 7, 2026; accession 0000882095-26-000024.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
